29th Napa Pain Conference (2022) - 2022 NPC Poster Hall - Neurovations

Novel Multispecialty Pain and Opioid Prescribing Oversight Clinic for a Large Military Medical Treatment Facility Can Have Major Safety Ramifications



Synopsis

Natural experiment quality improvement project with overall reduction in opioid prescriptions per 100 people by 49%. Achieving a greater reduction of opioid prescriptions than the U.S. and California each year (2016-2019) by at least 43.2% and as high as 67.5%. Categorized chronic pain patients (High Dose (HD), Moderate Dose (MD), Low Dose (LD) and Very Low Dose (VLD) defined by morphine equivalents of ³90, 50-89, 20-49) were reduced by 63.6%, 65.2%, 53.1% and 59.3% respectively. Categorized acute pain patients classified by Day’s Supply (DS) of opioid medication (1-8, 9-17 and > 18 DS) had reductions of 36.5%, 73.1% and 80.7% respectively.


Disclosures

  • Nothing to disclose by any author

Author(s):
Track: Poster

Tags: Pain Management Opioids

Display Label Action
Abstract - NPC2021 - White - Novel Multispecialty Pain and Opioid Download Abstract
Poster - NPC2021 - White - Novel Multispecialty Pain and Opioid Download Poster

Please use this thread to discuss the following:


Novel Multispecialty Pain and Opioid Prescribing Oversight Clinic for a Large Military Medical Treatment Facility Can Have Major Safety Ramifications


Synopsis

Natural experiment quality improvement project with overall reduction in opioid prescriptions per 100 people by 49%. Achieving a greater reduction of opioid prescriptions than the U.S. and California each year (2016-2019) by at least 43.2% and as high as 67.5%. Categorized chronic pain patients (High Dose (HD), Moderate Dose (MD), Low Dose (LD) and Very Low Dose (VLD) defined by morphine equivalents of ³90, 50-89, 20-49) were reduced by 63.6%, 65.2%, 53.1% and 59.3% respectively. Categorized acute pain patients classified by Day’s Supply (DS) of opioid medication (1-8, 9-17 and > 18 DS) had reductions of 36.5%, 73.1% and 80.7% respectively.


Disclosures

  • Nothing to disclose by any author